Literature DB >> 25841248

Ocular histoplasmosis syndrome.

Rocio I Diaz1, Eric J Sigler2, Mohammad R Rafieetary3, Jorge I Calzada4.   

Abstract

Ocular histoplasmosis syndrome (OHS) is a chorioretinal disorder with a distinct fundus appearance that is commonly found in regions endemic for Histoplasma capsulatum. Choroidal neovascularization (CNV) secondary to OHS is considered one of the principal causes of central vision loss among young adults in endemic areas. Although there is no consensus regarding its pathogenesis, evidence points to Histoplasma capsulatum as the most probable etiology. Once considered an intractable hemorrhagic maculopathy, CNVs are now treatable. Extrafoveal CNVs are successfully treated with laser photocoagulation. Subfoveal and juxtafoveal CNVs are managed with anti-vascular endothelial growth factor therapy, photodynamic therapy, or a combination of both. Modern imaging technologies such as spectral-domain optical coherence tomography have improved our diagnostic abilities, making it easier to monitor disease activity and CNV regression. We review the epidemiology, pathogenesis, clinical manifestations, differential diagnosis, and current treatment of this disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histoplasma capsulatum; anti-VEGF; bevacizumab; histoplasmosis; ocular histoplasmosis syndrome; photocoagulation; photodynamic therapy; presumed ocular histoplasmosis syndrome; ranibizumab; submacular surgery

Mesh:

Year:  2015        PMID: 25841248     DOI: 10.1016/j.survophthal.2015.02.005

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  8 in total

1.  Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy.

Authors:  T Barth; F Zeman; H Helbig; M-A Gamulescu
Journal:  Int Ophthalmol       Date:  2017-04-19       Impact factor: 2.031

Review 2.  LncRNAs in ocular neovascularizations.

Authors:  Yacouba Cissé; Lang Bai; Min-Ting Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

3.  Magnetic nanoparticles: a strategy to target the choroidal layer in the posterior segment of the eye.

Authors:  Martina Giannaccini; Lucia Pedicini; Guglielma De Matienzo; Federica Chiellini; Luciana Dente; Vittoria Raffa
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

Review 4.  Multi-modal imaging and anatomic classification of the white dot syndromes.

Authors:  Meisha L Raven; Alexander L Ringeisen; Yoshihiro Yonekawa; Maxwell S Stem; Lisa J Faia; Justin L Gottlieb
Journal:  Int J Retina Vitreous       Date:  2017-03-20

5.  EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.

Authors:  Timothy Y Y Lai; Giovanni Staurenghi; Paolo Lanzetta; Frank G Holz; Shiao Hui Melissa Liew; Sabine Desset-Brethes; Harry Staines; Philip G Hykin
Journal:  Retina       Date:  2018-08       Impact factor: 4.256

6.  A rare presentation of ocular histoplasmosis in a patient with systemic nocardiosis.

Authors:  Ranjan K Behera; Parul C Gupta; Surbhi Khurana; Shobha Sehgal; Suryaprakash Sharma; Jagat Ram
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 7.  Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature.

Authors:  Paola Zanotti; Claudia Chirico; Maurizio Gulletta; Laura Ardighieri; Salvatore Casari; Eugenia Quiros Roldan; Ilaria Izzo; Gabriele Pinsi; Giovanni Lorenzin; Fabio Facchetti; Francesco Castelli; Emanuele Focà
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 2.576

8.  SMOKING, RURAL RESIDENCE AND DIABETES AS RISK FACTORS FOR PRESUMED OCULAR HISTOPLASMOSIS SYNDROME.

Authors:  Brad F Richey; Rachel S Obrock; Zachary M Gee; David Y Lu; Gordon Jacobsen; Scott C Richards
Journal:  Retina       Date:  2022-02-01       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.